This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ronald Moy, MD; Yehuda D. Eliezri, MD

Arch Dermatol. 1994;130(2):235-238.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

HUMAN PAPILLOMAVIRUS (HPV) is now recognized as the possible cause of many skin diseases, including verrucae, condyloma acuminatum, Bowen's disease, keratoacanthomas, bowenoid papulosis, squamous cell carcinoma (SCC) in epidermodysplasia verruciformis (EV) and in immunosuppressed patients, and SCC of the nail bed and periungual area.¹ The reason for this ''epidemic'' of cutaneous HPV infection is unclear and requires further study. Because of the increased frequency of HPV infection seen in a dermatology practice, clinical dermatologists should be able to recognize the different clinical manifestations of cutaneous HPV infection, and should understand the implications of immunosuppression on HPV infection, the role of HPV infection in genital neoplasms, and the implications of HPV in the treatment of HPV-induced cutaneous SCC.

Evidence has recently been accumulating that HPV is the significant factor in the malignant transformation of certain cutaneous neoplasms. The strongest evidence for the cutaneous oncogenic potential of HPV is found in . . . [Full Text PDF of this Article]

Author Affiliations
100 UCLA Medical Plaza Suite 590 Los Angeles, CA 90024-6970; Department of Dermatology Columbia University 161 Fort Washington Ave New York, NY 10032

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?